Akèy › Myelom Miltip
Etid klinik pou Myelom Miltip ap rekrite nan Etazini
239 etid pou Myelom Miltip ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO26 etid
- Columbus, OH24 etid
- Rochester, MN24 etid
- Baldwin Park, CA23 etid
- St. Louis, MO23 etid
- Washington, DC22 etid
- Chicago, IL22 etid
- Edison, NJ22 etid
- Seattle, WA22 etid
- Charlotte, NC21 etid
- Milwaukee, WI21 etid
- Salt Lake City, UT21 etid
- Miami, FL21 etid
- Queens, NY20 etid
- Detroit, MI19 etid
- Jacksonville, FL18 etid
- Birmingham, AL18 etid
- Los Angeles, CA17 etid
- Cincinnati, OH17 etid
- Dallas, TX17 etid
- Cleveland, OH16 etid
- Phoenix, AZ16 etid
- Philadelphia, PA16 etid
- Omaha, NE16 etid
- Tampa, FL15 etid
- Cedar Rapids, IA15 etid
- San Francisco, CA15 etid
- Winston-Salem, NC14 etid
- New Haven, CT14 etid
- New Rochelle, NY14 etid
- Clifton, NJ14 etid
- Baltimore, MD13 etid
- Tacoma, WA13 etid
- Irvine, CA13 etid
Pa eta
- Alabama22 etid
- Arizona27 etid
- Arkansas9 etid
- Colorado36 etid
- Connecticut18 etid
- Delaware4 etid
- Distrik Columbia10 etid
- Florid55 etid
- Georgia49 etid
- Idaho3 etid
- Illinois31 etid
- Indiana19 etid
- Iowa17 etid
- Kalifòni70 etid
- Kansas12 etid
- Kentucky15 etid
- Lwizyàn9 etid
- Main3 etid
- Maryland25 etid
- Massachusetts44 etid
- Michigan26 etid
- Minnesota30 etid
- Missouri26 etid
- Montana4 etid
- Nebraska18 etid
- New Hampshire4 etid
- New Jersey38 etid
- New Mexico5 etid
- New York75 etid
- North Carolina52 etid
- North Dakota5 etid
- Ohio46 etid
- Oklahoma3 etid
- Oregon20 etid
- Pennsylvania23 etid
- Rhode Island6 etid
- South Carolina9 etid
- South Dakota3 etid
- Tennessee32 etid
- Texas53 etid
- Utah21 etid
- Virginia20 etid
- Washington30 etid
- West Virginia3 etid
- Wisconsin28 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07285044A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05519085Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06948084SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07850284Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Sep 30, 2026 · NCT06904066A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Ap rekriteFaz 2
Laj 18 a 72 · Tout sèks · Mizajou Sep 28, 2026 · NCT03412877Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT02682667A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05652335A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04973605Tissue Collection for Studies of Lymph Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT01676805A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07336472A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06768489A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05623020Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06052826A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07609940A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06500884A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04634552A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07149857A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.